Medical Innovations and Global Health Challenges Unveiled

Organon's arthritis biosimilar drug gets extended approval for critical immune reactions in cancer and COVID-19 patients. Some US employers plan to cease GLP-1 obesity drug coverage due to rising use. American efforts intensify to combat screwworm, threatening cattle amidst drought. Humana divests stake in Gentiva, while Ebola outbreak in Congo alarmingly spreads.

The U.S. FDA has broadened the application of Organon's arthritis biosimilar, a counterpart to Roche's Actemra, to treat dire immune reactions in cancer patients and COVID-19 cases requiring respiratory assistance.

With escalating usage of GLP-1 drugs, some US employers aim to drop weight-loss medication coverage by 2027, reversing some gains from reduced prices of popular brands Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Efforts to combat the New World screwworm intensify as the U.S. tries to shield its vulnerable cattle industry from the parasite amidst staffing challenges and preventive resource shortages.